Multiple Myeloma

Maneuvering the Complex Web of Treatment Options for Relapsed/Refractory Multiple Myeloma

Clinicians face a difficult task of deciding who to treat, when to treat, and how to treat especially since many factors need to considered when determining the optimal multiple myeloma (MM) treatment for relapsed/refractory MM including: age, prognostic factors, comorbidities, toxicity profiles,

Newly Diagnosed Multiple Myeloma: How Many Drugs are Enough?

A uniform treatment approach cannot be applied to all patients with multiple myeloma (MM). Clinicians must understand when to administer two-, three- or four or more drug regimens taking into consideration disease- and patient- characteristics. Illustrating how to individualize treatment plans will help educate health care providers about how to make best decisions in their own practice and improve outcomes of patients with newly diagnosed MM.

NCCN Guidelines® Insights - Multiple Myeloma, Version 3.2022

The NCCN Guidelines for Multiple Myeloma provide recommendations for diagnosis, initial workup, treatment, follow-up, and supportive care for patients with various plasma cell neoplasms, including multiple myeloma.

Monthly Oncology Tumor Boards: New Options in Treatment of Relapsed/Refractory Multiple Myeloma

In order to optimize patient outcomes, clinicians need to understand the evidence behind the current recommendations in the guidelines, the rationale for appropriate treatment selection, management of any treatment- or MM-specific adverse events, and emerging strategies.

New Treatment Options in Multiple Myeloma

Oncology nurses should understand the evolving therapeutic options available and the side effects related to those treatments as well as the current guidelines in the context of the patient's previous therapy and disease history to navigate the various options available.

Recorded Presentation from the NCCN Pharmacy Updates: Novel Agents for the Treatment of Relapsed/Refractory Multiple Myeloma

Several new options have recently been approved for the treatment of relapsed/refractory multiple myeloma. Pharmacists should be aware of the new data and recommendations surrounding these novel agents and how they relate to improvements in patient survival and quality of life.

NCCN Guidelines® Update: Multiple Myeloma

Clinicians must understand the evolving therapeutic options and guidelines for administration of the available therapies in the context of the patient's therapeutic and disease history to navigate through the complex treatment landscape.

Archived Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Multiple Myeloma

Clinicians must understand the treatment evolution and guidelines for administration of available therapies in the context of the patient's therapeutic and disease history to navigation through the complex treatment landscape.

NCCN Pharmacy Updates: Novel Agents for the Treatment of Relapsed/Refractory Multiple Myeloma